Collectively, these results highlight that, while GLP-1 remains central in incretin-based interventions, PYY has potential as an adjunct in multi-targeted therapeutic approaches for optimizing metabolic control in T2D. This evidence concerns the gene GCG and type 2 diabetes mellitus.